Hello and welcome to the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis. Here, we’ll highlight some of the most significant psychedelic industry news from the past month, including important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.

Emerging clinical trial data suggest that psychedelic compounds could benefit both millions of migraineurs and thousands of cluster headache sufferers who find limited benefit from even gold-standard treatments.

Conventional bioassays often require labeled detection reagents to provide a measurable readout. However, modifications to molecular structure and/or function can skew results, and non-specific binding of the labels themselves can lead to an unwanted background signal.

Download this guide to learn more about what RNA-Seq is and the information it provides, advantages of RNA-Seq, the types of RNA-Seq available and what to consider when designing your experiment.